Jones Rachael, Gazzard Brian
Department of HIV and GU Medicine, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK.
Int J STD AIDS. 2006 Aug;17(8):499-506. doi: 10.1258/095646206778145587.
With the advent of highly active antiretroviral therapy (HAART), the prognosis for HIV-infected individuals with access has been transformed. HAART provides one of the most cost-effective treatments for any chronic disease. Immediate cost remains a legitimate factor when choosing HAART regimens, however, the cost of long-term side-effects and adherence issues must also be considered. The review examines the cost issues associated with HAART prescription and its influence on prescribing policies.
随着高效抗逆转录病毒疗法（HAART）的出现，有机会接受该疗法的艾滋病毒感染者的预后得到了改善。HAART是治疗任何慢性病最具成本效益的方法之一。然而，在选择HAART方案时，直接成本仍然是一个合理的考虑因素，同时还必须考虑长期副作用和依从性问题的成本。这篇综述探讨了与HAART处方相关的成本问题及其对处方政策的影响。
